Insulin Human (Regular)

Regular insulin is short-acting human insulin, meaning it has the same amino acid sequence as the insulin produced naturally by the human body, with no engineered modifications ^[2]. It is also known as soluble or neutral insulin and is supplied as a clear solution ^[4]. Historically the hormone was extracted and purified from the pancreases of cattle and pigs, but since the 1980s it has been made almost entirely by recombinant DNA technology, in which bacteria or yeast are engineered to produce the human insulin protein ^[2].

Insulin was first isolated and used to treat a patient in 1922, following the work of Banting, Best, and colleagues in Toronto, a breakthrough that transformed type 1 diabetes from a fatal disease into a manageable one ^[2]. Regular insulin was the first form available ^[3]. The introduction of recombinant human insulin in the early 1980s, among the first products of the biotechnology industry, ended reliance on animal pancreases and provided a consistent, less immunogenic supply ^[2][4].

Regular insulin is used to control blood glucose in type 1 and type 2 diabetes and in gestational diabetes, typically injected under the skin before meals so that its onset coincides with the rise in blood sugar from food ^[4]. Because it can be given intravenously, it also has essential roles in the hospital treatment of diabetic ketoacidosis and hyperosmolar states and in lowering severe hyperkalemia when combined with glucose ^[2]. With the arrival of rapid-acting analogs such as lispro and aspart, which act faster and are more convenient because they can be taken right at mealtimes, the use of regular insulin for routine mealtime coverage has declined, though it remains widely used and important ^[4].

Regular insulin is available in vials and cartridges under brand names such as Humulin R, Novolin R, and Actrapid, and it is one of the few insulins that can be mixed with intermediate-acting insulin in the same syringe ^[4]. Its most important side effect, common to all insulins, is hypoglycemia, and it can also cause low blood potassium, injection-site reactions, changes in the fat under the skin at overused sites, weight gain, and, rarely, allergic reactions ^[2]. It is included on the World Health Organization list of essential medicines ^[2].

This is a prescription injectable and low blood sugar is the main danger, with symptoms like sweating, shaking, confusion, and, if severe, seizures or unconsciousness that need urgent sugar or glucagon. It also lowers blood potassium, which is useful when treating high potassium but must be watched otherwise. Injection sites can develop lumps if not rotated, and weight gain is common. Intravenous use requires hospital monitoring. As with other insulins, using it without diabetes to build muscle is very dangerous and has caused fatal low blood sugar, since a non-diabetic body has no need for the extra insulin and can crash without warning. Doses must be matched to food, and it should never be dosed casually.

Regular insulin traces its lineage to the original discovery of insulin by Frederick Banting, Charles Best, James Collip, and John Macleod at the University of Toronto in 1921 and 1922, a breakthrough that turned type 1 diabetes from a fatal disease into a manageable one and earned a Nobel Prize. For decades the hormone was purified from the pancreases of cattle and pigs, but a landmark advance came in 1978 when scientists at Genentech, working with the biotechnology of recombinant DNA, produced human insulin in bacteria.

This recombinant human insulin was commercialized by Eli Lilly as Humulin and approved in 1982, becoming the first recombinant protein drug ever marketed. Regular insulin retains the natural, unmodified amino acid sequence of human insulin, distinguishing it from the later engineered analogs. It remains essential in hospital practice for intravenous use in diabetic ketoacidosis and hyperkalemia, and it is listed by the World Health Organization as an essential medicine.

Regular insulin holds a place of enduring respect as the workhorse form of a hormone that has saved countless lives since the 1920s. Clinicians particularly value that it can be given intravenously, where its absorption delay disappears and it acts rapidly, making it the standard tool for managing diabetic emergencies such as ketoacidosis and for driving dangerously high blood potassium back into cells.

Its identical match to natural human insulin and its long track record give it a well-understood, predictable profile, and it remains far more affordable than newer analogs in many settings. The manufacture of recombinant human insulin is also celebrated as a founding achievement of the modern biotechnology industry. Honestly, its slower subcutaneous onset means it must be injected well before meals and carries a somewhat higher risk of between-meal lows than rapid-acting analogs, which is why analogs are often preferred for outpatient mealtime dosing.